206 related articles for article (PubMed ID: 27059141)
1. Development of a monoclonal antibody specific to envelope domain III with broad-spectrum detection of all four dengue virus serotypes.
Kim SH; Kim YN; Truong TT; Thu Thuy NT; Mai LQ; Jang YS
Biochem Biophys Res Commun; 2016 May; 473(4):894-898. PubMed ID: 27059141
[TBL] [Abstract][Full Text] [Related]
2. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
[TBL] [Abstract][Full Text] [Related]
3. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
4. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection.
Wan SW; Chen PW; Chen CY; Lai YC; Chu YT; Hung CY; Lee H; Wu HF; Chuang YC; Lin J; Chang CP; Wang S; Liu CC; Ho TS; Lin CF; Lee CK; Wu-Hsieh BA; Anderson R; Yeh TM; Lin YS
J Immunol; 2017 Oct; 199(8):2834-2844. PubMed ID: 28904127
[TBL] [Abstract][Full Text] [Related]
7. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
[TBL] [Abstract][Full Text] [Related]
8. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
[TBL] [Abstract][Full Text] [Related]
9. [Preparation and identification of neutralizing antibodies to envelope protein domain III(ED III) of the four dengue virus serotypes].
Ding X; Qiu L; Chen Y; Wen K
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Aug; 38(8):748-753. PubMed ID: 35851089
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
[TBL] [Abstract][Full Text] [Related]
11. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection.
Ali S; Afzal S; Yousaf MZ; Shahid M; Amin I; Idrees M; Aftab A
Crit Rev Eukaryot Gene Expr; 2020; 30(3):199-206. PubMed ID: 32749106
[TBL] [Abstract][Full Text] [Related]
13. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
Hu D; Zhu Z; Li S; Deng Y; Wu Y; Zhang N; Puri V; Wang C; Zou P; Lei C; Tian X; Wang Y; Zhao Q; Li W; Prabakaran P; Feng Y; Cardosa J; Qin C; Zhou X; Dimitrov DS; Ying T
PLoS Pathog; 2019 Jun; 15(6):e1007836. PubMed ID: 31242272
[TBL] [Abstract][Full Text] [Related]
14. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
Lisova O; Belkadi L; Bedouelle H
J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.
Falconar AK
Clin Vaccine Immunol; 2008 Mar; 15(3):549-61. PubMed ID: 18160621
[TBL] [Abstract][Full Text] [Related]
16. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1).
Gelanew T; Poole-Smith BK; Hunsperger E
J Virol Methods; 2015 Sep; 222():214-23. PubMed ID: 26070890
[TBL] [Abstract][Full Text] [Related]
18. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III.
Matsui K; Gromowski GD; Li L; Schuh AJ; Lee JC; Barrett AD
Virology; 2009 Feb; 384(1):16-20. PubMed ID: 19101005
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus.
Kim J; Lim TY; Park J; Jang YS
J Microbiol; 2023 Jan; 61(1):131-143. PubMed ID: 36723792
[TBL] [Abstract][Full Text] [Related]
20. Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1.
Zou G; Kukkaro P; Lok SM; Ng JK; Tan GK; Hanson BJ; Alonso S; MacAry PA; Shi PY
Antiviral Res; 2012 Sep; 95(3):216-23. PubMed ID: 22771779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
